85,761 Shares in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Purchased by Tema Etfs LLC

Tema Etfs LLC bought a new position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 85,761 shares of the company's stock, valued at approximately $1,087,000. Tema Etfs LLC owned approximately 0.09% of Day One Biopharmaceuticals as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the company. SG Americas Securities LLC bought a new position in Day One Biopharmaceuticals during the 4th quarter worth $866,000. MetLife Investment Management LLC increased its holdings in Day One Biopharmaceuticals by 12.4% in the fourth quarter. MetLife Investment Management LLC now owns 34,248 shares of the company's stock worth $434,000 after purchasing an additional 3,781 shares in the last quarter. Hennion & Walsh Asset Management Inc. lifted its stake in Day One Biopharmaceuticals by 90.6% in the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 121,167 shares of the company's stock valued at $1,535,000 after buying an additional 57,601 shares during the period. Charles Schwab Investment Management Inc. grew its position in shares of Day One Biopharmaceuticals by 5.5% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 535,501 shares of the company's stock worth $6,785,000 after buying an additional 28,053 shares during the period. Finally, Bank of New York Mellon Corp grew its stake in shares of Day One Biopharmaceuticals by 43.4% in the 4th quarter. Bank of New York Mellon Corp now owns 244,829 shares of the company's stock valued at $3,102,000 after buying an additional 74,091 shares during the period. 87.95% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, CEO Jeremy Bender sold 13,964 shares of the company's stock in a transaction on Friday, May 16th. The shares were sold at an average price of $6.26, for a total value of $87,414.64. Following the transaction, the chief executive officer now owns 145,737 shares of the company's stock, valued at approximately $912,313.62. This represents a 8.74% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, General Counsel Adam Dubow sold 4,552 shares of the business's stock in a transaction dated Friday, May 16th. The stock was sold at an average price of $6.26, for a total value of $28,495.52. Following the transaction, the general counsel now owns 47,136 shares of the company's stock, valued at approximately $295,071.36. The trade was a 8.81% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 26,725 shares of company stock worth $167,299 over the last 90 days. Corporate insiders own 6.20% of the company's stock.

Day One Biopharmaceuticals Trading Up 0.3%

Shares of DAWN stock traded up $0.02 on Friday, hitting $6.29. 293,605 shares of the stock were exchanged, compared to its average volume of 1,246,380. The firm's 50 day moving average is $7.27 and its two-hundred day moving average is $10.59. Day One Biopharmaceuticals, Inc. has a one year low of $6.08 and a one year high of $16.76. The firm has a market capitalization of $637.57 million, a PE ratio of -6.11 and a beta of -1.24.

Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.46) by $0.11. The business had revenue of $30.76 million during the quarter, compared to the consensus estimate of $30.28 million. On average, sell-side analysts expect that Day One Biopharmaceuticals, Inc. will post -0.72 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages have commented on DAWN. Wedbush reissued an "outperform" rating and issued a $25.00 price objective on shares of Day One Biopharmaceuticals in a research note on Wednesday, May 7th. HC Wainwright restated a "buy" rating and set a $36.00 price objective on shares of Day One Biopharmaceuticals in a report on Thursday, April 3rd. The Goldman Sachs Group reduced their price objective on shares of Day One Biopharmaceuticals from $39.00 to $27.00 and set a "buy" rating for the company in a report on Tuesday, March 25th. Needham & Company LLC lowered their target price on shares of Day One Biopharmaceuticals from $30.00 to $27.00 and set a "buy" rating on the stock in a report on Wednesday, May 7th. Finally, JPMorgan Chase & Co. decreased their price objective on Day One Biopharmaceuticals from $39.00 to $34.00 and set an "overweight" rating for the company in a report on Wednesday, March 5th. Seven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of "Buy" and an average target price of $30.57.

Day One Biopharmaceuticals Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.